OBJECTIVES: To evaluate in vivo the contribution of tumour necrosis factor alpha (TNFalpha) to the chimeric transfer model of human rheumatoid arthritis synovial membrane into SCID mice (hu/mu SCID arthritis), systemic anti-TNFalpha treatment was performed and the clinical, serological, and histopathological effects of this treatment assessed. METHODS: Animals were treated with the rat-antimouse TNFalpha monoclonal antibody V1q, starting on day 1 after hu/mu engraftment, twice weekly for 12 weeks. Joint swelling, serum concentrations of human and murine interleukin 6 (IL6), and serum amyloid P (SAP) were measured. Histopathological and immunohistochemical analyses of the joints were also performed at the end of treatment. RESULTS: Neutralisation of murine TNFalpha induced the following effects: (a) reduction of extent and duration of the acute arthritis phase, with significant reduction of joint swelling at two weeks; (b) decrease of murine SAP concentrations after the first antibody administration; and (c) increase of murine IL6 in the serum. At the end of treatment, there was a significant reduction of the inflammatory infiltration in the engrafted joints. Because of the mild degree of joint erosion, no treatment effects could be demonstrated on the destructive process. CONCLUSION: In the lymphocyte independent hu/mu SCID arthritis, anti-TNFalpha treatment reduces local and systemic signs of inflammation.
OBJECTIVES: To evaluate in vivo the contribution of tumour necrosis factor alpha (TNFalpha) to the chimeric transfer model of humanrheumatoid arthritis synovial membrane into SCIDmice (hu/mu SCID arthritis), systemic anti-TNFalpha treatment was performed and the clinical, serological, and histopathological effects of this treatment assessed. METHODS: Animals were treated with the rat-antimouse TNFalpha monoclonal antibody V1q, starting on day 1 after hu/mu engraftment, twice weekly for 12 weeks. Joint swelling, serum concentrations of human and murineinterleukin 6 (IL6), and serum amyloid P (SAP) were measured. Histopathological and immunohistochemical analyses of the joints were also performed at the end of treatment. RESULTS: Neutralisation of murineTNFalpha induced the following effects: (a) reduction of extent and duration of the acute arthritis phase, with significant reduction of joint swelling at two weeks; (b) decrease of murine SAP concentrations after the first antibody administration; and (c) increase of murineIL6 in the serum. At the end of treatment, there was a significant reduction of the inflammatory infiltration in the engrafted joints. Because of the mild degree of joint erosion, no treatment effects could be demonstrated on the destructive process. CONCLUSION: In the lymphocyte independent hu/mu SCID arthritis, anti-TNFalpha treatment reduces local and systemic signs of inflammation.
Authors: G Kojouharoff; W Hans; F Obermeier; D N Männel; T Andus; J Schölmerich; V Gross; W Falk Journal: Clin Exp Immunol Date: 1997-02 Impact factor: 4.330
Authors: D M Butler; A M Malfait; L J Mason; P J Warden; G Kollias; R N Maini; M Feldmann; F M Brennan Journal: J Immunol Date: 1997-09-15 Impact factor: 5.422
Authors: P L Van Lent; F A Van De Loo; A E Holthuysen; L A Van Den Bersselaar; H Vermeer; W B Van Den Berg Journal: J Rheumatol Date: 1995-12 Impact factor: 4.666
Authors: J Lewthwaite; S Blake; T Hardingham; R Foulkes; S Stephens; L Chaplin; S Emtage; C Catterall; S Short; A Nesbitt Journal: Ann Rheum Dis Date: 1995-05 Impact factor: 19.103
Authors: Laurie S Davis; Marian Sackler; Ruth I Brezinschek; Ellis Lightfoot; Jennifer L Bailey; Nancy Oppenheimer-Marks; Peter E Lipsky Journal: Am J Pathol Date: 2002-01 Impact factor: 4.307
Authors: Katina Schinnerling; Carlos Rosas; Lilian Soto; Ranjeny Thomas; Juan Carlos Aguillón Journal: Front Immunol Date: 2019-02-19 Impact factor: 7.561